Volume : 12, Issue : 06, June – 2025

Title:

PLEIOTROPIC EFFECTS OF METFORMIN: FROM CELLULAR TARGETS TO SYSTEMIC OUTCOMES

Authors :

Chillimunta Bhavani, Saroyar Reja, Mehedi Hasan, Subiya Maheen, Panala Teja Sri Mahalaxmi, Md Ashik Malithya, Narender Boggula*

Abstract :

Metformin is the first-choice therapy to lower glycaemia and manage type 2 diabetes. Continuously emerging epidemiological data and experimental models are showing additional protective effects of metformin against a number of age-related diseases (ARDs), e.g., cardiovascular diseases and cancer. Metformin, classified as a biguanide oral antidiabetic agent, is predominantly prescribed as the primary treatment for type 2 diabetes mellitus. Its role as a therapeutic agent is expanding to include the treatment of pre-diabetes, gestational diabetes, polycystic ovarian disease and the treatment or prevention of preeclampsia. Beyond its primary role in regulating blood sugar, it also provides several secondary health advantages. These include protective cardiovascular effects, potential roles in managing COVID-19, assistance with weight control particularly in PCOS, and promising anti-cancer, anti-aging, and neuroprotective properties. This review summarizes recent studies supporting these diverse effects and discusses the methodologies of significant research efforts. Particular focus is given to metformin’s mechanisms of action, key clinical trials, and observational studies that demonstrate its extended therapeutic utility.
Key words: Metformin, COVID-19, polycystic ovarian syndrome, anti-aging, neurodegenerative disorders, Galega officinalis.

Cite This Article:

Please cite this article in press Narender Boggula al., Pleiotropic Effects Of Metformin: From Cellular Targets To Systemic Outcomes, Indo Am. J. P. Sci, 2025; 12(06).

Number of Downloads : 10

References:

1. Bailey CJ. Metformin: Historical Overview. Diabetologia. 2017; 60:1566–1576.
2. Bailey CJ, Day C. Metformin: Its Botanical Background. Pract. Diabetes Int. 2004; 21:115–117.
3. American Diabetes Association. Standards of care in diabetes-2023 abridged for primary care providers. Clin Diabetes. 2023; 41(1):4–31.
4. Bailey CJ. Biguanides and NIDDM. Diabetes Care. 1992; 15:755–772.
5. Khan FN., Hirsch IB. Diabetes and the WHO Model List of Essential Medicines. Lancet Diabetes Endocrinol. 2022; 10:16–17.
6. Defronzo RA, Goodman AM. Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. The Multicenter Metformin Study Group. N Engl J Med. 1995; 333:541–549.
7. Witters LA. The blooming of the French lilac. J Clin Invest. 2001; 108(8):1105–1107.
8. Yerevanian A, Soukas AA. Metformin: mechanisms in human obesity and weight loss. Curr Obes Rep. 2019; 8(2):156–164.
9. Rosenstock J, Chuck L, Gonzalez-Ortiz M, Merton K, Craig J, Capuano G, et al. Initial combination therapy with canagliflozin plus metformin versus each component as monotherapy for drug-naive type 2 diabetes. Diabetes Care. 2016; 39:353–362.
10. Softeland E, Meier JJ, Vangen B, Toorawa R, Maldonado-Lutomirsky M, Broedl UC. Empagliflozin as add-on therapy in patients with type 2 diabetes inadequately controlled with linagliptin and metformin: a 24-week randomized, double-blind, parallel-group trial. Diabetes Care. 2017; 40:201–209.
11. Yki-Jarvinen H, Ryysy L, Nikkila K, Tulokas T, Vanamo R, Heikkila M. Comparison of bedtime insulin regimens in patients with type 2 diabetes mellitus. A randomized, controlled trial. Ann Intern Med. 1999; 130:389–396.
12. Wulffele MG, Kooy A, Lehert P, Bets D, Ogterop JC, Borger Van Der Burg B, et al. Combination of insulin and metformin in the treatment of type 2 diabetes. Diabetes Care. 2002; 25:2133–2140.
13. Lin Y, Wang K, Ma C, Wang X, Gong Z, Zhang R, et al. Evaluation of metformin on cognitive improvement in patients with non-dementia vascular cognitive impairment and abnormal glucose metabolism. Front Aging Neurosci. 2018; 10:227
14. Inoki K, Zhu T, Guan KL. TSC2 mediates cellular energy response to control cell growth and survival. Cell. 2003; 115(5):577–590.
15. Xu CX, Zhu HH, Zhu YM. Diabetes and cancer: associations, mechanisms, and implications for medical practice. World J Diabetes. 2014; 5(3):372–380.
16. Ballotari P, Vicentini M, Manicardi V, et al. Diabetes and risk of cancer incidence: results from a population-based cohort study in northernItaly. BMC Cancer. 2017; 17(1):703.
17. Giovannucci E, Harlan DM, Archer MC, et al. Diabetes and cancer: a consensus report. Diabetes Care. 2010; 33(7):1674–1685.
18. Bjornsdottir HH, Rawshani A, Rawshani A, et al. A national observation study of cancer incidence and mortality risks in type 2 diabetes compared to the background population over time. Sci Rep. 2020; 10(1):17376.
19. Froldi G. View on Metformin: Antidiabetic and Pleiotropic Effects, Pharmacokinetics, Side Effects, and Sex-Related Differences. Pharmaceuticals (Basel). 2024; 17(4):478.
20. Yu H, Pardoll D, Jove R. STATs in cancer inflammation and immunity: a leading role for STAT3. Nat Rev Cancer. 2009; 9(11):798–809.
21. Soranna D, Scotti L, Zambon A, et al. Cancer risk associated with use of metformin and sulfonylurea in type 2 diabetes: a meta-analysis. Oncologist. 2012; 17(6):813–822.
22. Thakkar B, Aronis KN, Vamvini MT, Shields K, Mantzoros CS. Metformin and sulfonylureas in relation to cancer risk in type II diabetes patients: a meta-analysis using primary data of published studies. Metabolism. 2013; 62(7):922–934.
23. Mekuria AN, Ayele Y, Tola A, Mishore KM. Monotherapy with metformin versus sulfonylureas and risk of cancer in type 2 diabetic patients: a systematic review and meta-analysis. J Diabetes Res. 2019;7676909.
24. Wu Y, Liu HB, Shi XF, Song Y. Conventional hypoglycaemic agents and the risk of lung cancer in patients with diabetes: a meta-analysis. PLoS One. 2014; 9(6):e99577.
25. Alimova IN, Liu B, Fan Z, et al. Metformin inhibits breast cancer cell growth, colony formation and induces cell cycle arrest in vitro. Cell Cycle. 2009; 8(6):909–915.
26. Harada N. Effects of Metformin on Blood Glucose Levels and Bodyweight Mediated through Intestinal Effects. J. Diabetes Investig. 2020; 11:1420–1421.
27. Agius L, Ford BE, Chachra SS. The Metformin Mechanism on Gluconeogenesis and AMPK Activation: The Metabolite Perspective. Int. J. Mol. Sci. 2020; 21:3240.
28. Foretz M., Guigas B., Viollet B. Metformin: Update on Mechanisms of Action and Repurposing Potential. Nat. Rev. Endocrinol. 2023; 19:460–476.
29. Bonnet F, Scheen A. Understanding and Overcoming Metformin Gastrointestinal Intolerance. Diabetes Obes. Metab. 2017; 19:473–481.
30. Stefanis L. α-synuclein in Parkinson’s disease. Cold Spring Harb Perspect Med. 2012; 2(2):a009399.
31. Wakabayashi K, Tanji K, Mori F, Takahashi H. The Lewy body in Parkinson’s disease: molecules implicated in the formation and degradation of alpha-synuclein aggregates. Neuropathology. 2007; 27(5):494–506.
32. Piriz J, Muller A, Trejo JL, Torres-Aleman I. IGF-I and the aging mammalian brain. Exp Gerontol. 2011; 46(2–3):96–99.
33. Saewanee N, Praputpittaya T, Malaiwong N, Chalorak P, Meemon K. Neuroprotective effect of metformin on dopaminergic neurodegeneration and α-synuclein aggregation in C. elegans model of Parkinson’s disease. Neurosci Res. 2021; 162:13–21.